Improved dihydroergotamine (DHE) pharmacology following orally-inhaled delivery

被引：0
|
作者：
Cook, R. O. [1 ]
Shrewsbury, S. B. [1 ]
机构：
[1] MAP Pharmaceut Inc, Res & Dev, Mountain View, CA USA
来源：
HEADACHE | 2008年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S62 / S63
页数：2
相关论文
共 50 条
  • [21] MAP0004, Orally Inhaled Dihydroergotamine for Acute Treatment of Migraine: Efficacy of Early and Late Treatments
    Tepper, Stewart J.
    Kori, Shashidhar H.
    Goadsby, Peter J.
    Winner, Paul K.
    Wang, Min H.
    Silberstein, Stephen D.
    Cutrer, F. Michael
    MAYO CLINIC PROCEEDINGS, 2011, 86 (10) : 948 - 955
  • [22] Pharmacokinetic Comparison of STS101, an Intranasal Dry Powder Formulation of Dihydroergotamine, with Other Intranasal, Injectable and Oral Inhaled DHE Formulations
    Strom, Shannon
    Albrecht, Detlef
    Kollins, John
    NEUROLOGY, 2020, 94 (15)
  • [23] A Thorough QT Study Comparing Supratherapeutic Dose of Orally Inhaled DHE, Moxifloxacin, and Placebo on the QT Interval in Healthy Volunteers
    Jividen, H.
    Haugen, G.
    Kellerman, D.
    Kori, S.
    Heyman, E.
    Elhard, M.
    HEADACHE, 2011, 51 : 21 - 22
  • [24] A thorough qt study comparing supratherapeutic dose of orally inhaled dhe, moxifloxacin, and placebo on the qt interval in healthy volunteers
    Jividen, H.
    Haugen, G.
    Kellerman, D.
    Kori, S.
    Elhard, M.
    Heyman, E.
    CEPHALALGIA, 2011, 31 (01) : 65 - 65
  • [25] TOWARDS AN IN VITRO BIOASSAY FOR DRUG DELIVERY FROM ORALLY INHALED PRODUCTS
    Muddle, Joanna
    Kanabar, Varsha
    Brown, Marc
    Page, Clive
    Forbes, Ben
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2016, 29 (03) : A17 - A17
  • [26] An Open-Label, 2-Period, Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult Volunteers
    Forst, Amy
    Febbraro, Salvatori
    Kellerman, Don
    Kori, Shashidhar
    Tann, Lan
    Thomas, Tracy
    NEUROLOGY, 2011, 76 (09) : A197 - A197
  • [27] MAP0004, an orally inhaled formulation of DHE, delivers faster and more consistent therapeutic blood levels of the drug compared to traditional oral, subcutaneous, intramuscular, and intranasal formulations of DHE
    Kori, S. H.
    Shrewsbury, S. B.
    Wong, M.
    HEADACHE, 2008, 48 : S63 - S63
  • [28] An Open-Label, Two-Period Crossover Study Comparing the Pharmacokinetics and Tolerability of LEVADEX™ (MAP0004, Orally Inhaled DHE) and Intravenous DHE (DHE45®) in Smoking and Non-Smoking Adult Volunteers
    Forst, A.
    Febbraro, S.
    Kellerman, D.
    Kori, S.
    WuTann, L.
    Thomas, T.
    Taylor, G.
    HEADACHE, 2011, 51 : 17 - 17
  • [29] Sensitivity Analysis and Uncertainty Quantification in Pulmonary Drug Delivery of Orally Inhaled Pharmaceuticals
    Lu, Jun
    Xi, Jinxiang
    Langenderfer, Joseph E.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (11) : 3303 - 3315
  • [30] A long-term open-label study assessing the safety and tolerability of levadex® orally inhaled dihydroergotamine in adult migraineurs
    Kellerman, D.
    Chang, J.
    Kori, S.
    CEPHALALGIA, 2011, 31 (01) : 32 - 33
12345